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Gene dosage is a key defining factor to understand cancer pathogenesis and progression, which requires the development of
experimental models that aid better deconstruction of the disease. Here, we model an aggressive form of prostate cancer and
show the unconventional association of LKB1 dosage to prostate tumorigenesis. Whereas loss of Lkb1 alone in the murine
prostate epithelium was inconsequential for tumorigenesis, its combination with an oncogenic insult, illustrated by Pten
heterozygosity, elicited lethal metastatic prostate cancer. Despite the low frequency of LKB1 deletion in patients, this event
was significantly enriched in lung metastasis. Modeling the role of LKB1 in cellular systems revealed that the residual activity
retained in a reported kinase-dead form, LKB1K78I, was sufficient to hamper tumor aggressiveness and metastatic
dissemination. Our data suggest that prostate cells can function normally with low activity of LKB1, whereas its complete
absence influences prostate cancer pathogenesis and dissemination.
Introduction
Prostate cancer (PCa) is primarily diagnosed as a localized disease
that is considered curable with first-line therapies. However, two
major limitations exist in its clinical management (Chang et al.,
2014). First, a considerable proportion of men will relapse after
such treatments. These patients will frequently fail to respond to
subsequent lines of treatment (androgen pathway inhibitors and
chemotherapy) and succumb to metastatic PCa. Second, a fraction
of PCa patients will exhibit metastatic disease at diagnosis.
Whereas the incidence of this phenomenon is estimated as <10% in
populations heavily prescreened for prostate-specific antigen, it is
thought to account for ≤50% of PCa mortality (James et al., 2015).
The clinicalmanagement of lethal metastatic disease is the ultimate
challenge in PCa. However, the success in recapitulating this
phenomenon in experimental models has been limited (Arriaga
and Abate-Shen, 2019).
LKB1 (the protein encoded by the gene STK11) is amaster kinase
with a prominent role as a tumor suppressor in various tissue
types. This gene is mutated and deleted in lung, cervix, uterine,
skin, and pancreatic cancers (Momcilovic and Shackelford, 2015).
The study of LKB1 in cancer has been boosted by the development
of mouse models with varying doses of the tumor suppressor,
which result in a reduction of its levels of 50–100% (for hetero-
zygous and homozygous knockout mice, respectively; Pearson
et al., 2008) or 25–75% (through the combination of hypomor-
phic alleles withWT or knockout alleles, respectively; Huang et al.,
2008).
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Tumor suppressors are clinically and experimentally defined
based on gene dosage. Knudson (1971) proposed that genes with
such functions would follow the two-hit hypothesis, according
to which cancer would emerge upon the loss of the second allele
in cells with carrying a mutated gene. However, we know that
the relationship between gene dosage and tumor-suppressive
activity is more complex, which led to the introduction of con-
cepts such as haploinsufficient tumor suppressors (Berger et al.,
2011). However, further experimental effort is required for a
comprehensive classification of tumor suppressors, based on
evidence produced through the analysis of mouse models with
hypomorphic alleles (Alimonti et al., 2010).
In this study, we generate an unprecedented model of lethal
metastatic PCa by introducing perturbations in Lkb1 in a pre-
cancerous setting and demonstrate the high competence of this
kinase to suppress biological features of PCa.
Results and discussion
To ascertain the role of LKB1 in PCa, we engineered a series of
Lkb1 prostate-specific mutant mice based on a conditional mouse
model (Fig. S1, A–D; see Materials and methods; Nardella et al.,
2010; Pearson et al., 2008). The survival of mice with prostate-
specific Lkb1 (Lkb1pc−/−) deficiency was indistinguishable from
that of control counterparts (Fig. 1 A). Although Lkb1 deletion led
to increased tissue mass (Fig. S1 E), it did not result in any his-
tological alteration (Fig. 1 B). These data are in contrast to results
obtained using other Cre recombinases such as p450 CYP1A1-
driven Cre, which show a broader tissue distribution in the
urogenital track (Pearson et al., 2008). The discrepancies might
be associated with the impact of the non-prostate epithelial de-
letion of Lkb1 (Pearson et al., 2008). Also, the original description
of this Cre driver reported expression inmultiple tissues and cell
types beyond the prostate (Ireland et al., 2004). Our results using
a well-established prostate epithelium–restricted Cre driver
support the notion that Lkb1 loss is not an initiating event in
prostate tumorigenesis.
Next, we evaluated whether deletion of Lkb1 would contribute
to PCa pathogenesis in the presence of an oncogenic event. To this
end, we intercrossed prostate-conditional Lkb1 knockout mice
with a well-established driver of murine PCa, Pten knockout mice
(Fig. S1, C and D). Whereas Ptenpc−/− mice develop nonmetastatic
PCa, the phenotype of heterozygous mice is limited to prostate
intraepithelial neoplasia (PIN; Nardella et al., 2010). Surprisingly,
the deletion of Lkb1 resulted in a remarkable reduction in survival
when combinedwith one allele deletion of Pten (Fig. 1 C). Since the
combination of Pten heterozygosity with Lkb1 loss (hereafter re-
ferred to as PTLK) resulted in early lethality, we performed his-
tological characterization of all genotypes at 10 mo of age. PTLK
mice exhibited PCa at full penetrance, whereas none of the other
genotypes (Ptenpc+/− Lkb1pc+/+, Ptenpc+/− Lkb1pc+/−) presented lesions
beyond PIN at the same age (Fig. 1 D). Moreover, the macroscopic
and histopathological analysis of distant organs unexpectedly re-
vealed that PTLK mice developed lung metastasis with an inci-
dence >80% (justifying their reduced survival rate) and inguinal
lymph node colonization to a lower extent (Fig. 1, E and F). Im-
portantly, lung lesions were histologically identical to the prostatic
tumor and exhibited positive staining for androgen receptor (AR),
supporting the notion that the metastases were of prostatic origin
(Fig. S1 F). No lesionswere observed in heart, liver, spleen, kidney,
or bone (Table S1).
PCa disseminates predominantly to bone. However, dissemi-
nation to lungs is well recognized to occur in 10–20% of metastatic
disease (Arriaga and Abate-Shen, 2019). We took advantage of
publicly available PCa transcriptomics and genomics studies to
ascertain the alteration of LKB1 in primary and metastatic lesions.
We started by evaluating point mutations in a series of PCa
datasets (Taylor et al., 2010, Cancer Genome Atlas Research
Network, 2015; Kumar et al., 2016; Abida et al., 2017, 2019;
Fraser et al., 2017; Armenia et al., 2018; Gerhauser et al., 2018)
using cBioPortal (Cerami et al., 2012; Gao et al., 2013). The results
revealed a lack of this type of alteration in PCa compared with a
compendium of datasets from lung adenocarcinoma (Cancer
Genome Atlas Research Network, 2013; Imielinski et al., 2012;
Jordan et al., 2017), a tumor type with frequent alterations in LKB1
(Fig. S1 G). We next focused on genomic aberrations using a large-
scale study of PCa (n = 1,013), in which primary tumor biopsies
and metastatic specimens where sequenced and tropism was an-
notated (Armenia et al., 2018). In this dataset, LKB1 heterozygosity
was observed in 24.6% of cases (249 out of 1,013), whereas com-
plete loss was restricted to 3.36% of specimens (34 of 1,013; Table
S2), in turn suggesting that LKB1 is not a commonly aberrant
tumor suppressor in the prostate. However, we noted that meta-
static tumors had higher rates of LKB1 genomic aberrations, with
4.8% of homozygous deletions (16 of 333) compared with 2.65% in
primary tumors (18 of 680), and 29.1% of heterozygous loss (97 of
333) compared with 22.35% in primary tumors (152 of 680; χ2 P =
0.007). We decided to analyze whether perturbations in this gene
could be associated with any specific metastatic behavior. 66% of
metastatic cases presented site annotation (220 of 333). Metastatic
cases within this subset with one or two intact alleles of LKB1
exhibited similar distribution of metastasis, with a predominance
of bone and lymph node dissemination and negligible lung me-
tastasis (Fig. 1 G and Table S3). Among the limited number of
metastatic cases with homozygous deletion of LKB1, 50% belonged
to lung metastatic specimens (2 of 4; Fig. 1 G). The incidence of
LKB1 homozygous deletionwas 28.6% (2 of 7, Fisher’s exact test P <
0.01) in lung metastasis compared with 0.9% (2 of 213) of all other
metastatic specimens, whereas we found no enrichment in bone
metastasis or lymph node dissemination (Fig. 1 H, Fig. S1 H, and
Table S3).
As a complementary approach, we analyzed an independent
cohort (Kumar et al., 2016) in which we compared the expres-
sion of LKB1 in the two predominant metastatic sites of interest,
bone versus lung. In agreement with our previous results, lung
metastatic lesions exhibited a significant reduction in the ex-
pression of the kinase (Fig. 1 I).
Taking advantage of the aforementioned large genomic da-
taset (Armenia et al., 2018), we explored the genetic events that
could co-occur with LKB1 in metastatic specimens. To this end,
we extracted from this dataset the most frequent copy number
alterations (Table S4) and evaluated their association to LKB1
deletion in metastasis. We noted that none of the classic PCa
oncogenic mutations were cooccurring with LKB1 deletion
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Figure 1. Combined Lkb1 loss with Pten heterozygosity in murine prostate epithelia results in PCa progression and dissemination. (A) Cumulative
survival curve (Kaplan–Meier survival plot) of Lkb1pc+/+ (n = 27) and Lkb1pc−/− (n = 27) mice. The cumulative survival rate was plotted against age in weeks.
(B) Histopathological characterization of the prostate in the indicated genotypes Lkb1pc+/+ (n = 7) and Lkb1pc−/− (n = 19) mice (left). LGPIN, low-grade PIN.
Representative image of H&E staining of normal prostate in Lkb1pc+/+ mice (right, upper panel) and Lkb1pc−/−mice (right, lower panel). (C) Cumulative survival curve
(Kaplan–Meier survival plot) of Ptenpc+/− Lkb1pc+/+ (n = 9), Ptenpc+/− Lkb1pc+/− (n = 23), and Ptenpc+/− Lkb1pc−/− (n = 21) mice. The cumulative survival rate was plotted
against age in weeks. (D) Histopathological characterization of the prostate in the indicated genotypes: Ptenpc+/− Lkb1pc+/+ (n = 4), Ptenpc+/− Lkb1pc+/− (n = 5), and
Ptenpc+/− Lkb1pc−/− (n = 18) mice (left). Right panels depict representative H&E micrographs of the histological features observed in each genotype. A macroscopic
image of a representative tumor in Ptenpc+/− Lkb1pc−/− mice is included. HGPIN, high-grade PIN. (E) Quantification of the frequency of lymph node colonization in
Ptenpc+/− Lkb1pc+/+ (n = 8), Ptenpc+/− Lkb1pc+/− (n = 9), and Ptenpc+/− Lkb1pc−/− (n = 13) mice (left). Representative image of H&E staining of a normal lymph node in
Ptenpc+/− Lkb1pc+/+ (right, upper panel) and a lymph node metastasis in Ptenpc+/− Lkb1pc−/− mice (right, lower panel). Red arrows depict colonizing prostate tumor
cells. (F) Quantification of the frequency of metastatic lesions in lung of Ptenpc+/− Lkb1pc+/+ (n = 4), Ptenpc+/− Lkb1pc+/− (n = 7), and Ptenpc+/− Lkb1pc−/− (n = 14) mice
(left). Representative macroscopic image (right, upper panel) and representative histopathological image (right, lower panel) of metastatic lesions in lung in
Ptenpc+/− Lkb1pc−/−mice. (G) Incidence of metastatic lesions in bone, lymph nodes, lung, liver, and other tissues in patients with metastatic PCa with indicated LKB1
genomic status. Numbers below the graph indicate total number of analyzed metastatic samples. Dataset of origin: Armenia et al. (2018). (H) Incidence of LKB1
genomic alterations in metastatic specimens of patients with metastatic PCa (Armenia et al., 2018). Cases without LKB1 homozygous deletion (LKB1 not homdel);
cases with LKB1 homozygous deletion (homdel). Not bone, metastasis identified in all analyzed tissues except for bone; not lung, metastasis identified in all
analyzed tissues except for lung. Numbers below the graph indicate total number of analyzed metastatic samples. (I) Gene expression levels of LKB1 in bone and
lung metastatic samples in patients with PCa (Kumar et al., 2016). pc, prostate-specific allelic changes; +, WT allele; −, deleted allele; n.s., not significant;
**, P < 0.01; ***, P < 0.001. Statistic tests: log-rank (Mantel–Cox) test (A and C), Fisher exact test (H), two-tailed unpaired Student’s t test (I).
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(Table S5). These data led us to speculate that the aggressive
features enabled upon LKB1 loss are not associated with a single
oncogenic hit, but rather to the process of transformation itself.
In this regard, we envision the perturbation in Pten used in the
mouse model as an illustrative oncogenic signal that would un-
leash prostate cell proliferation and enable the emergence of Lkb1
loss–dependent phenotypes.
LKB1 phosphorylates 13 different effector kinases (Lizcano
et al., 2004). To ascertain which of the potential targets of LKB1
could account for its prostate tumor–suppressive activity, we
asked whether any of these targets would phenocopy the pattern
of genomic loss of the master regulator using the same patient
dataset (Armenia et al., 2018). When looking at the loci of the
aforementioned kinases, we found genomic aberrations in only
nine of them. Among these genes, we identified the strongest
pattern of lung dissemination in SIK3 (Fig. S1 I). Similar to LKB1,
SIK3 homozygous deletion was present in 28.6% (2 of 7, Fisher’s
exact test P < 0.01) of all lung metastatic cases (Fig. S1 J and Table
S6). Interestingly, accounting for metastatic specimens with ho-
mozygous deletion in LKB1 and/or SIK3 increased the incidence in
lung metastasis in this group to nearly 50% (3 of 7; Fisher’s exact
test P < 0.01; Fig. S1 K and Table S7). It is worth noting that the low
number of specimens with alterations in these genes precluded a
more conclusive result. The potential involvement of SIK3 in the
prostate tumor–suppressive activity of LKB1 is coherent with re-
cent reports in non–small cell lung cancer (Hollstein et al., 2019;
Murray et al., 2019), in turn suggesting that the LKB1-SIK tumor
suppressive axis might be relevant in different cancer types.
The aggressive nature of PCa in PTLK mice prompted us to
characterize the molecular and pathological features of these tu-
mors. PTLK prostate tissues exhibited reduced AMPK phospho-
rylation and elevated activity of mTOR complex 1 (by means of
ribosomal protein S6 phosphorylation), in line with the reported
inhibitory activity of LKB1 on this pathway (Momcilovic and
Shackelford, 2015; Fig. S2, A and B). The histological analysis of
PTLK lesions revealed that these tumors presented squamous
features, with elevated p63 positivity and Krt5 expression, in
line with observations in other tumor types (Momcilovic and
Shackelford, 2015; Fig. S2, B and C). We then compared the mo-
lecular features in PCa with intact Lkb1 (Ptenpc−/−, PIN or adeno-
carcinoma as indicated) or Lkb1 complete deletion (PTLK mice,
squamous cell carcinoma). PIN lesions retained a well-defined
layer of basal prostate cells, characterized by cytokeratin 5/6
(CK5/6) and p63, which were lost in invasive lesions (Fig. 2 A), in
line with the notion that these tumors emerge from the aberrant
proliferation of luminal cells (Arriaga and Abate-Shen, 2019). In
contrast, prostate tumors and metastases in PTLK mice were
predominantly composed of CK5/6- and p63-positive basal pros-
tate cells and exhibited transcriptional signatures of squamous cell
carcinoma in prostate tumor microdissected specimens (Fig. 2 A,
Fig. S2 D, and Table S8). In agreement, prostate squamous cell
carcinoma lesions from PTLK mice exhibited a 10-fold increase in
basal cell proliferation, shown by Ki67, compared with adeno-
carcinoma lesions (Fig. S2 E). Our results support the notion that
PCa in PTLK mice develops predominantly from the aberrant
proliferation of basal cells, leading to highly metastatic squamous
cell carcinoma.
The vast majority of available PCa high-throughput molecular
studies focus on adenocarcinoma lesions, since this histological
cancer type is predominant. However, according to PCa guidelines,
squamous cell carcinoma of prostate presents an incidence of
0.5–1% and exhibits highly aggressive characteristics (Brunnhoelzl
and Wang, 2018; Munoz et al., 2007). We searched for LKB1-
deficient PCa specimens that exhibited squamous pathological
features. Interestingly, we identified three such cases (Fig. 2 B).
Two of the three cases exhibited positivity for 34βE12, a basal cell
marker, whereas one case showed weak positivity. Interestingly,
two of these three specimens harbored combined LKB1 and PTEN
alterations, analogous to our murine model (Fig. 2 B).
To approach the mechanism by which LKB1 suppresses PCa,
we characterized a panel of PCa cells. In line with previous re-
ports, DU145 cells lack LKB1 protein expression, due to a frame-
shift homozygous mutation (Ikediobi et al., 2006; Fig. 3 A). We
took advantage of this cell line and reintroduced LKB1 at expres-
sion levels comparable to other prostate cells. As a technical
control, we also reexpressed a reported kinase activity-defective
mutant, LKB1K78I (Fig. 3 B and Fig. S2 F; Shaw et al., 2004).
Whereas reintroduction of LKB1 did not affect two-dimensional
cell growth (Fig. S2 G), we observed a remarkable inhibition of
migration, invasion, invasive growth, and anchorage-independent
growth in bothWT and K78I mutant LKB1-expressing cells (Fig. 3,
C–E; and Fig. S2 H). We extended our studies to xenograft assays.
At the level of both subcutaneous tumor growth and metastatic
dissemination, LKB1 was tumor suppressive regardless of its ki-
nase activity (Fig. 3, F–I; and Fig. S2, I and J).
The results with LKB1K78I were suggestive of an unprece-
dented kinase-independent tumor-suppressive activity. We
ruled out this possibility by different means. On the one hand,
we evaluated the correct and equivalent formation of the
LKB1 complex in cells (Boudeau et al., 2003; Momcilovic and
Shackelford, 2015). By both coimmunoprecipitation coupled to
Western blot and mass spectrometry analysis, we could dem-
onstrate that LKB1WT and LKB1K78I presented equivalent protein
interaction profiles with core components of its functional
complex, including MO25, STE20-related adaptor, HSP90 and
CDC37 (Fig. S3, A and B; and Table S9). On the other hand, the
kinase-independent effect could be due to the sequestration of
MO25 away from other STK family proteins. MO25A was the
predominant isoform in these cells (Fig. S3 C). We hypothesized
that, if the tumor suppressive activity of both LKB1 constructs
relied on the sequestration of MO25, silencing this gene would
mimic LKB1 expression and elicit tumor suppression. However, the
silencing of this adaptor protein did not reduce two-dimensional or
anchorage-independent growth (Fig. S3, D–F).
The lack of evidence supporting a kinase-independent tumor
suppressive function of LKB1 prompted us to carefully monitor
the impact of K78I mutation on the activity of the kinase. Sur-
prisingly, LKB1K78I retained 10% of theWT activity (Fig. 4 A). We
evaluated the impact of LKB1 expression on the activity of its
targets. In line with our clinical observations, the phosphoryl-
ation of SIK1-3 was increased by LKB1WT and to a lower extent
by the K78I mutant (Fig. 4 B), and this effect was retained, albeit
with lower amplitude, when monitoring AMPK activity (Fig. S3,
G and H). To ascertain whether the residual activity of LKB1K78I
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is sufficient to exert tumor suppression, we generated a second
mutant, harboring a nucleotidic change in the magnesium-
binding domain (D194A; Lizcano et al., 2004) that we con-
firmed to be fully devoid of kinase activity (Fig. 4 C and Fig. S3 I).
Importantly, compared with the deleted parental cells, the ex-
pression of LKB1D194A neither activated SIK1-3 nor influenced the
signaling pattern or the biological response in vitro and in vivo,
as opposed to LKB1WT or LKB1K78I mutant (Fig. 4, D–G; and Fig.
S3, J–O). Altogether, our results demonstrate that loss of LKB1 is
associated with the emergence of squamous features in murine
PCa and that the kinase requires minimal activity to suppress
aggressive PCa features in cellular systems.
PCa is a highly prevalent disease in men. Although it is
generally considered curable with first-line therapies, a fraction
of patients will exhibit biochemical recurrence associated with
the failure on subsequent therapeutic alternatives (Chang et al.,
2014). These men will eventually develop metastatic disease,
thus accounting for the mortality of the disease, together with
those individuals that exhibit metastatic PCa at presentation
(James et al., 2015). Bone is the predominant site of metastasis in
this disease, although a subset of highly aggressive PCa dis-
seminates to the lung and soft tissues (Arriaga and Abate-Shen,
2019). The biology of lethal metastatic PCa is poorly understood,
and there are few murine models to date that recapitulate this
Figure 2. Histological characterization of prostate tumors with LKB1 deficiency. (A) Immunostaining images of H&E, CK5/6, p63, and Ki67 in squamous
cell carcinoma of prostate (Ptenpc+/− Lkb1pc−/− mice), lung metastasis (Ptenpc+/− Lkb1pc−/− mice), PIN lesions (Ptenpc−/− Lkb1p+/+ mice), and adenocarcinoma
(Ptenpc−/− Lkb1p+/+ mice). (B) Immunohistochemical images of H&E (left, upper panels) and 34βE12 (left, lower panels) in PCa specimens with squamous
features. Right panels depict the status of LKB1 (genomic) and PTEN (genomic and protein).
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pattern of aggressiveness (Arriaga and Abate-Shen, 2019). Our
study provides the field with an invaluable model to study the
process of PCa dissemination in an immune-competent and
tissue-specific context. Importantly, our patient dataset analysis
using the largest cohort available (Armenia et al., 2018) shows
that homozygous deletion in LKB1 is rare in PCa (2.6% in primary
tumors and 4.8% in metastasis), and point mutations are negli-
gible. Despite this low frequency of LKB1 homozygous deletion,
we find an association of this event with metastasis in the lung.
It is important to note that our data in murine models and hu-
man specimens is insufficient to postulate a role for LKB1 in
metastatic tropism. However, together with the in vitro assays,
our data indicate that LKB1 deletion results in the acquisition of
aggressiveness features, which would enable prostate tumor
cells to gain access to the lung instead of the long metastatic
process that underlies bone colonization.
Figure 3. WT and mutant LKB1K78I exert
significant tumor suppressive activity. (A)
Western blot analysis of LKB1 protein expression
in a normal prostate epithelial cell line (PWR1E)
and in a panel of PCa cell lines (technical dupli-
cates are shown). Representative image from
three independent experiments is shown.
(B) Western blot analysis of LKB1 protein ex-
pression in DU145 cell line with ectopic expression
of WT Flag-LKB1 (LKB1WT), the Flag-LKB1-K78I
mutant (LKB1K78I), or transduced with mock
vector (pBABE) using 22RV1 cells as a positive
control (n = 3). Representative image from
three independent experiments is shown. (C–E)
Quantification (left) and representative image
(right) of anchorage-independent growth (C; n = 8,
independent experiments), migration (D; n = 6,
independent experiments), and invasive growth
(E; n = 5, independent experiments). Black circle
highlights the original size of the spheroid and
dashed line highlights the size of the spheroid after
48 h of incubation in DU145 cells with ectopic
expression of LKB1WT or LKB1K78I or transduced
with mock (pBABE). Data are normalized to con-
trol (pBABE; dashed line). (F and G) Effect of LKB1
reconstitution in DU145 cells with ectopic ex-
pression of LKB1WT or LKB1K78I or transduced with
mock (pBABE) on tumor formation (F) and tumor
weight (G; left). n = 13–14 tumors per condition.
(H and I) Evaluation of metastatic capacity of
control (pBABE) and LKB1WT- and LKB1K78I-ex-
pressing DU145 cells using intracardiac xenotrans-
plant assays. Luciferase-based signal intensity of
DU145 cells in limbs was monitored in vivo (H; n as
indicated) and ex vivo (I; mean signal of both tibia
was calculated and presented; n as indicated in the
dot plot) for ≤38 d. Representative luciferase im-
ages are presented referred to the quantification
plots. Statistic tests: one-sample t test (C–E), one-
tailed unpaired Student’s t test (F and G), one-
tailed Mann–Whitney U test (H and I). *, P <
0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
Error bars represent SEM.
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Lkb1 deletion is associated with the onset of metastatic disease
in other tumor types when combined with perturbation of dif-
ferent cancer genes (Momcilovic and Shackelford, 2015). Over-
all, experimental evidence suggests that loss of LKB1 is not an
initiating event in cancer, but rather an enhancer of aggressive
features once oncogenic signaling is present. Following this line
of reasoning, and in line with our patient analysis, it is tempting
to speculate that the oncogenic signaling provides a proliferative
advantage to cells, regardless of the cancer gene perturbed, that
will unleash the metastasis-suppressor potential of LKB1.
Figure 4. LKB1 is a high-competence prostate tumor suppressor. (A) Evaluation of LKB1 kinase activity of DU145 cell line with ectopic expression of LKB1WT
or LKB1K78I or transduced with mock (pBABE). Representative data from three independent experiments. (B) Western blot analysis for LKB1, SIK1-3 phospho-
rylation, and HSP90 protein expression in control and LKB1WT- and LKB1K78I-expressing cells. The asterisk indicates a nonspecific band. Representative image from
three independent experiments is shown. (C) Evaluation of LKB1 kinase activity of DU145 cell line with ectopic expression of LKB1WT, LKB1K78I, or LKB1D194A or
transduced with mock (pBABE). Representative data from two independent experiments. (D)Western blot analysis for LKB1, SIK1-3 phosphorylation, and β-actin
protein expression in control, LKB1WT-, LKB1K78I-, and LKB1D194A-expressing cells. Representative image from three independent experiments is shown. (E) Effect
of LKB1WT, LKB1K78I, and LKB1D194A expression on anchorage-independent growth (n = 3, independent experiments). Data are normalized to control (pBABE;
dashed line). (F) Effect of LKB1 reconstitution in DU145 cells with ectopic expression LKB1WT, the kinase-defective mutants (LKB1K78I, LKB1D194A) or infected with
mock vector (pBABE) on tumor formation in xenotransplantation experiments (n = 20 injections per condition). (G) Metastatic capacity of control (pBABE),
LKB1WT-, LKB1K78I-, and LKB1D194A-expressing DU145 cells using intracardiac xenotransplant assays. Quantification (left) and representative tibia view (right) of
luciferase-dependent signal intensity of DU145 cells in ex vivo tibia analysis on day 42 after injection (mean signal of both tibias was calculated and presented; n as
indicated in the dot plot). (H) Schematic representation of the proposed classification of tumor suppressors according to their competence. Flox, results based on
tissue-specific conditional mousemodels. Red filling, oncogenic features associated to dose reduction. Statistic tests: one-tailed unpaired Student’s t test (A, C, and
F); one-sample t test (E), one-tailed Mann–Whitney U test (G). n.s., not significant; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
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Squamous cell carcinoma is included in the clinical guidelines
as a highly aggressive subtype of PCa, with an incidence
of 0.5–1% and average survival of 14 mo after diagnosis
(Brunnhoelzl and Wang, 2018; Munoz et al., 2007). The combi-
nation of Pten and Lkb1 deletion in the prostate epithelium per-
formed in this study results in aggressive squamous cell prostate
carcinoma. In line with the notion that basal prostate cells have
reduced androgen requirements (Xie et al., 2017), PTLK tumors
exhibit delocalized or negative AR expression. It is worth
highlighting the different cellular compartments that contribute
to PCa aggressiveness upon loss of tumor suppressors. Lkb1 loss
affects basal cell proliferation. In contrast, deletion in other tu-
mor suppressors such as Tp53 predominantly favors luminal cell
renewal and expansion (Agarwal et al., 2015). Importantly,
whereas the incidence is low in human PCa, mouse models of
PCa are more prone to exhibit squamous features (Ittmann et al.,
2013; Martin et al., 2011). In addition, several studies report that
Lkb1 deletion in different tissues predisposes to squamous lesions
(Momcilovic and Shackelford, 2015). Specifically, combined de-
letion of Pten and Lkb1 in the lung was recently reported as the
first bona fide mouse model of lung squamous cell carcinoma
(Xu et al., 2014). Interestingly, the existence of compound LKB1
and PTEN deletions in human prostate tumors with squamous
pathological and molecular features opens an avenue of research
toward better understanding of this disease.
The introduction of hypomorphic alleles inmousemodels has
enabled the fine-tuning of dosage beyond the use of gene
knockouts. Taking advantage of this technology, we previously
reported that Pten is a weak breast tumor suppressor, since the
introduction of a hypomorphic allele in heterozygosity (70–75%
of WT Pten expression) resulted in breast cancer (Alimonti et al.,
2010). The combined use of conditional mouse models and LKB1
mutant in cells in this study provides strong support for the
notion that this kinase is a potent prostate tumor suppressor that
can operate at very low doses. Moreover, our analysis of the
mutant LKB1K78I provides a feasible explanation for the discor-
dance of our results with the elegant study performed by Huang
et al. (2008). Using a whole-body hypomorphic Lkb1 mutant
mouse combined with systemic Pten heterozygous deletion, they
observed that there was Lkb1 dose-dependent acceleration of
various cancerous lesions. However, Pten+/−;Lkb1Hy/Hy mice did
not exhibit alterations in prostate pathology compared with
Pten+/−;Lkb1+/+. Our report, together with past results from our
group and others, suggests that classic genetic dosage dis-
tributions or definitions such as haploinsufficiency are unable to
correctly define the extent of their role in cancer.
We put forward the concept of tumor suppressive “compe-
tence” as a defining feature of tumor suppressors, taking PTEN
and LKB1 as illustrative genes (Fig. 4 H). We define standard
competence as a continuum of reduction in tumor suppression
capacity along with the dosage, which is recapitulated in the
prostate phenotype of Ptenmutantmice (Nardella et al., 2010; Chen
et al., 2005; Di Cristofano et al., 1998; Trotman et al., 2003). We
define low competence as a reduction of <50% when a tumor
suppressor gene dose results in cancerous lesions, as reported in
the mammary tissue with Pten mutants expressing 75% of Pten
(Alimonti et al., 2010) and at lower gene doses by others (Stambolic
et al., 2000; Li et al., 2002). The integration of our results with the
study of the group of Alessi (Huang et al., 2008) justifies the def-
inition of LKB1 as a prostate tumor suppressor with high compe-
tence. In this context, reduction of the gene dosage of 50%
(heterozygous) or 70% (hypomorphic) is inconsequential for PCa
development. Moreover, retention of LKB1 activity as low as 10% is
sufficient for the kinase to exert tumor suppression in vitro and
in vivo. Only complete deletion of this gene is associated with the
pathogenesis of PCa, a genetic condition that turns a premalignant
disease (PIN, typical of Pten+/−mice) into lethal metastatic PCa. It is
worth noting that the introduction of competence in the definition
of tumor suppressors remains a conceptual implementation, based
on the integration of results derived from conditional and germline
mouse models of two exemplifying genes, PTEN and LKB1. Further
research is warranted to explore the relevance of this concept for
other tumor suppressors, but it could harbor therapeutic relevance,
since it would help establish the extent of pathway reactivation
required for targeted therapies to show clinical effectiveness.
Materials and methods
Genetically engineered mouse models
The conditional tissue-specific phosphatase and tensin homologue
(Pten) knockout (C57/BL6/129sv; Pb-Cre4; Pten lox/lox) model
was kindly provided by Pier Paolo Pandolfi (Beth Israel Deaconess
Cancer Center, Boston, MA). The conditional tissue-specific Lkb1
null homogeneous backgroundmodel (FVB;Lkb1lox/lox) was from
Mouse Models of Human Cancer Consortium in a pure FVB
background. First, we backcrossed this line into C57BL/6J for four
generations to obtain animals with genetic background enriched
in C57/BL6 (>90% C57/BL6). Next we crossed Lkb1lox/lox mice
with Pb-cre4 and Pten lox/lox mice for at least four generations to
obtain a founder colony with mixed homogeneous background,
and experimental animals were generated. Littermates where
analyzed when possible. However, due to the complexity of the
allele combination, the different genotypes of interest with Pten
and/or Lkb1 alteration were obtained from parallel contemporary
breeding pairs. Probasin Cre was always retained in male mice,
since in females Pb-Cre4 expression in utero can lead to recom-
bination in embryos during pregnancy. The Cre recombinase
expression, under the control of androgen-dependent ARR2B
probasin promoter (Pb-Cre4), allowed the deletion of Pten in the
prostate epithelium at puberty. Prostate Pten/Lkb1-deleted male
mice were termed pc−/+ (heterozygous) or pc−/− (homozygous
knockout) for each gene.
Patient cohort and ethics approval
Patients were identified from a cohort of men with advanced
castrate-resistant PCa treated at the Royal Marsden National
Health Service Foundation Trust. All patients had given written
informed consent and were enrolled in institutional protocols
approved by the Royal Marsden Hospital (London, UK) ethics
review committee (reference no. 04/Q0801/60).
Generation of stable cell lines
DU145 cells expressing WT LKB1 (LKB1WT), LKB1 K78I (LKB1K78I),
and LKB1 D194A (LKB1D194A) mutants were generated by retroviral
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gene transfer. pBABE-puro (Addgene plasmid 1764; RRID:Add-
gene_1764) was a gift from Hartmut Land (Imperial Cancer Re-
search Fund, Lincoln’s Inn Fields, London, UK), JayMorgenstern,
and Bob Weinberg (Whitehead Institute for Biomedical Re-
search, Cambridge, MA; Morgenstern and Land, 1990). pBABE-
FLAG-LKB1 (Addgene plasmid 8592; RRID:Addgene_8592) and
pBABE-FLAG-KD LKB1 (Addgene plasmid 8593; RRID:Add-
gene_8593) were a gift from Lewis Cantley (Meyer Cancer Center,
New York, NY; Shaw et al., 2004). pBabe-FLAG-LKB1-D194A was
a gift from Dr. Bin Zheng (Columbia University, New York, NY).
Lentiviral shRNA constructs targeting MO25α (TRCN0000044254;
TRCN0000044256) were purchased from Sigma-Aldrich, and a
scramble shRNA (hairpin sequence: 59-CCGGCAACAAGATGAAGA
GCACCAACTCGAGTTGGTGCTCTTCATCTTGTTG-39) was used as
control. pLKO.1 puro was a gift from Bob Weinberg (Addgene
plasmid 8453; RRID:Addgene_8453; Stewart et al., 2003).
HEK293FT cells were transfected with retroviral or lentiviral
vectors following standard procedures, and viral supernatant
was used to infect cells. Selection was done using puromycin
(2 µg/ml; Sigma-Aldrich).
Cell culture
Human prostate carcinoma cell lines PC3, DU145, and LNCaP
were purchased from Leibniz-Institut Deutsche Sammlung von
Mikroorganismen und Zellkulturen GmbH, who provided an
authentication certificate. Human prostate cell line PWR1E and
human prostate carcinoma cell lines 22RV1 and VCaP were
purchased from ATCC. HEK293FT and C4-2 were generously
provided by the laboratories of Rosa Barrio (CIC bioGUNE, Derio,
Spain) and Pier Paolo Pandolfi, respectively. Cell lines were
periodically subjected to microsatellite-based identity valida-
tion. The cell lines used in this study were not found in the
database of commonly misidentified cell lines maintained by the
International Cell Line Authentication Committee and National
Center for Biotechnology Information Biosample. All cell lines
were routinely monitored for mycoplasma contamination and
quarantined while treated if positive. DU145, PC3, VCaP, and
293FT cell lines were maintained in DMEM supplemented with
10% (vol/vol) FBS (Gibco) and 1% (vol/vol) penicillin-streptomycin
(Gibco). LNCap, C4-2, and 22RV1 cell lines were maintained in
RPMI supplemented with 10% (vol/vol) FBS and 1% (vol/vol)
penicillin-streptomycin. PWR1E cell line was maintained in Ke-
ratinocyte Serum Free Medium (Gibco) supplemented with
0.05 mg/ml bovine pituitary extract (Gibco) and 5 ng/ml epider-
mal growth factor (Gibco).
Cellular assays
Cell proliferation
1 × 104 cells were plated in triplicate in 12-well dishes.
Quantification was performed as reported (Torrano et al.,
2016). Anchorage-independent growth was tested by the
ability to grow in soft agar as described previously (Torrano
et al., 2016). The cell migration and invasion assay was per-
formed in a 24-well-size Transwell plate of 8-µm pores (BD
Falcon 351185). The invasive growth assay was performed as
referenced (Martı´n-Martı´n et al., 2018) using the hanging
drop method.
Anchorage-independent growth
A 6-well tissue culture dish was coated with the bottom agar
layer (complete DMEM containing 0.6% agar; SeaKem LE aga-
rose, Lonza) and stored at 4°C for ≥30min to let the agar solidify.
Cells (2,500 cells/well) were resuspended in a 0.3% low-
melting-point agar (Agarose LM, Pronadisa, Conda) and plated
on top of the bottom agar. The plates were incubated (37°C and
5% CO2) for 4 wk for growth of colonies. Colonies were counted
using Fiji software.
Cell migration assay
Cells (50,000 cells/well) were resuspended in final volume of
500 µl 0.1% FBS DMEM and seeded in the upper part of the
chamber. The bottom part was filled with 1.4 ml of complete
DMEM. Plates were maintained at 37°C and 5% CO2 for 24 h.
Nonmigrated cells from the upper surface of the membrane
were carefully removed by rinsing with PBS and using a cotton
swab. The membrane was fixed with 10% formalin (15 min at
4°C) and stained with crystal violet. Transwell invasion was
performed using Matrigel-coated chambers (Corning BioCoat
Matrigel Invasion Chamber). After an incubation period of 48 h
(37°C and 5% CO2), membrane washing and fixation were per-
formed under the same conditions as in the migration assay.
Both Transwell assays were evaluated by photomicrographs
from five randomly chosen fields (100×) per membrane. The
number of migrated or invaded cells was counted using Fiji.
Invasive growth assay
28,000 cells were resuspended in a final volume of 500 µl
DMEM with 6% methylcellulose (Sigma-Aldrich, M0387). Drops
(25 µl/drop) were pipetted on the cover of a 100-mm culture
plate. The inverted plates were incubated at 37°C and 5% CO2 for
48 h. Once formed, spheroids were collected, resuspended in
collagen I solution (1.7 mg/ml in DMEM), and seeded into 24-
well plates that were maintained at 37°C and 5% CO2 for 48 h.
The area of the invading spheroids was measured using Fiji.
Relative invasive growth was quantified as area difference on
day 2 minus day 0.
Xenotransplant assays
All mouse experiments were performed following the ethical
guidelines established by the Biosafety andWelfare Committee at
the Center for Cooperative Research in Biosciences as previously
described (Mart´ın-Mart´ın et al., 2018; Torrano et al., 2016). The
procedures employed were performed following the recom-
mendations from Association for Assessment and Accreditation
of Laboratory Animal Care. DU145 cells (pBABE, LKB1WT,
LKB1K78I, and LKB1D194A; 4 × 106 cells per site) were resuspended
in a final volume of 100 µl cold PBS supplemented with glucose
(5 µM) mixed with 50 µl of Matrigel (Corning) and injected
subcutaneously in two flanks per 6–12-wk-old male athymic nude
mouse. Measurement of tumor size was performed three times a
week, and tumor volume was estimated using the following for-
mula: volume = length × width2 × 0.526. After euthanasia, tumors
were weighed, and tissue was fresh frozen or fixed overnight
in 10% neutral buffered formalin, embedded in paraffin, sec-
tioned 3-µm thick, and dried. Proliferation was assessed in
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dewaxed and rehydrated slides using Ki67 antibody (MA5-
14520, Thermo Fisher Scientific).
Metastasis assays
All animal studies were performed according with the institu-
tional animal care and use committee of Institute for Research in
Biomedicine, Barcelona, Spain. For these studies, male BALB/c
nude mice (Harlan) were used (12 wk old). Before cell injection,
mice were anaesthetized as previously described (Torrano et al.,
2016). Using a 26-G needle, 500,000 cells were injected into the
left cardiac ventricle of mice resuspended in 1× PBS. Luciferase
activity from the bone legs was detected by IVIS imaging. Data
were processed using Living Image software. Photon Flux was
measured every week for 38–42 d and normalized to values
obtained on day 0. Ex vivo tibia analysis was performed in those
mice with evidence of bioluminescence signal above background
and that survived for the entire experiment.
Histopathologic analysis, immunohistochemistry,
and immunofluorescence
Tissue sample collection (prostate gland, lymph nodes, long bones
from lower limbs, lungs, and liver) was performed at 18 mo of
age (LKB1pc+/+ and LKB1pc−/− mice) or 10 mo of age (Ptenpc+/−
LKB1pc+/+, Ptenpc+/− LKB1pc+/−, and Ptenpc+/− LKB1pc−/−). Tissue
samples were fixed overnight in 10% neutral buffered formalin,
embedded in paraffin, sectioned 3-µm thick, and dried. Slides
were dewaxed and rehydrated through a series of graded ethanol
to water and stained with the required antibody and/or H&E.
Histological observations on H&E-stained tissues were per-
formed using an Olympus DP73 digital camera. Prostatic lesions
were histologically classified according to the criteria of the
Consortium Prostate Pathology Committee (Shappell et al.,
2004) and scored as 0, no lesion observed; 1, focal or multifo-
cal low-grade PIN; 2, focal or multifocal high-grade PIN; 3,
carcinoma affecting <50% of tissue; 4, carcinoma affecting >50%
of tissue. SPCs originate from squamousmetaplasia of neoplastic
prostatic epithelial cells. Lungs metastasis were described as
micrometastasis when neoplastic cell growth in a small focus or
multifocal or severe metastasis when neoplastic cells progressed
involving multiple or large lung regions. Lymph node lesions
were scored as follows: 0, no lesion observed; or 1, metastasis.
A standard immunohistochemistry protocol was applied.
Briefly, slides were deparaffinized, and antigen retrieval was
performed in a pressure cooker in citric acid buffer, pH 6
(phospho-S6, p63) or EDTA, pH 8 (phospho-AMPK). Sections
were then immersed in 3% hydrogen peroxide to block endog-
enous peroxidase activity and washed in PBS. Incubation with
specific blocking serum for 30 min was followed by incubation
with primary antibodies at 4°C overnight using the following
concentrations: phospho-AMPK (CST, 2535, 1:50), phospho-S6
(CST, 4858, 1:500), p63 (Abcam, ab735, 1:100), and AR (Santa
Cruz Biotechnology, N-20, 1:200). The next day, after washing in
PBS, signal was amplified with avidin/biotin technology (Vec-
tastain Elite ABC system) or ImmPress HRP IgG (Peroxidase)
Polymer Detection Kit (Vector Laboratories) and visualized with
ImmPact DABSubstrate (Vector Laboratories). Finally, tissues
were counterstained with H&E.
CK5/6 (Ventana, 790-4554, ready to use, cytoplasmic staining),
p63 (Ventana, 790-4509, ready to use, nuclear staining), and Ki67
(Ventana, 790-4286, ready to use, nuclear staining) stains were
performed in automated immunostainers (BenchMark Ultra,
Ventana Medical Systems) following routine methods. Tris-EDTA
was used for antigen retrieval. Negative controls were slides not
exposed to the primary antibody, and these were incubated in PBS
and then processed under the same conditions as the test slides.
The analysis was performed using a Nikon Eclipse 80imicroscope.
High molecular weight CK immunohistochemistry was per-
formed on the Bond RX automated platform (Leica Micro-
systems) using a mouse monoclonal anti–high molecular weight
CK antibody (Abcam, ab776, clone 34βE12). Heat-induced epitope
retrieval was achieved with Bond Epitope Retrieval Solution
2 (Leica Microsystems, AR9640) for 20 min at 100°C before in-
cubation with primary antibody (1:100 dilution) for 15 min at
room temperature. The reaction was visualized using the Bond
Polymer Refine Detection system (DS9800, Leica Microsystems).
PTEN immunostaining and scoring criteria was done fol-
lowing the procedure in Ferraldeschi et al. (2015). Proliferative
basal epithelium cells were identified by staining with Ki67
(Thermo Fisher Scientific, 1/200, 14-5698-82) and CK5 (Bio-
Legend, 1/500, PRB-160P) primary antibodies. For quantifica-
tion of double-positive cells, five independent sections from five
independent mice were counted using ImageJ 1.52a (National
Institutes of Health).
LKB1 kinase activity
LKB1 kinase activity was measured as described previously
(Lizcano et al., 2004). Cells stably overexpressing LKB1 WT,
K78I, or D194A mutants (FLAG-tagged), were used to immuno-
precipitate anti-FLAG-agarose resin, in triplicate. Reactions
were performed in FLAG-agarose immunoprecipitates from
1.5 mg protein, using 200 µM NuaKtide as peptide and 100 µM
32P-ATP as substrates in a 60-min reaction. 1 mU of LKB1 kinase
activity is the amount that catalyzed the phosphorylation of
1 pmol of NuaKtide in 1 min in the standard assay at 30°C.
Quantitative real-time PCR (qRT-PCR)
RNA was extracted using NucleoSpin RNA isolation kit
(Macherey-Nagel, 740955.240C). For animal tissues, a Trizol-based
implementation of the NucleoSpin RNA isolation kit protocol
was used as reference (Ugalde-Olano et al., 2015). For all cases, 1 µg
of total RNA was used for cDNA synthesis using Maxima HMinus
cDNA Synthesis Master Mix (Thermo Fisher Scientific, M1682).
qRT-PCR was performed as previously described (Carracedo et al.,
2012). Universal Probe Library primers (Roche) and probes (Roche
and Thermo Fisher Scientific) are detailed in Table S10. All qRT-
PCR data presented were normalized using GAPDH/Gapdh (Ap-
plied Biosystems, Hs02758991_g1, Mm99999915_g1).
Western blot
Western blot was performed as previously described (Carracedo
et al., 2012). Briefly, cells were lysed in radioimmunoprecipitation
assay buffer (50 mM Tris-HCl, pH 7.5, 150 mMNaCl, 1 mM EDTA,
0.1% SDS, 1% Nonidet P40, 1% sodium deoxycholate, 1 mM sodium
fluoride, 1 mM sodium orthovanadate, 1 mM β-glycerophosphate,
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and protease inhibitor cocktail; Roche). Antibodies used were
phospho-AMPK substrate motif (CST 5759), phospho-ACC (CST
11818), phospho-AMPK (CST 2535), LKB1 (CST 3050), MO25α/
CAB39 (CST 2716s), PTEN (CST 9559), phospho-Raptor (CST
2083), Raptor (CST 2280), β-actin (CST 3700S), and HSP90 (CST
4874). All antibodies were used at a 1:1,000 dilution except β-actin
at 1:2,000. Mouse and rabbit secondary antibodies were pur-
chased from Jackson Immunoresearch. After standard SDS-PAGE
and Western blotting techniques, proteins were visualized using
the enhanced chemiluminescence.
Proteomics
Immunoprecipitation
Cells were lysed in immunoprecipitation buffer (40 mM Tris-
HCl, pH 7.5, 1 mM EDTA, 150 mM NaCl, 0.5% Triton X-100,
150 mMNaCl, 1 mMMgCl2, 1 mM sodium fluoride, 1 mM sodium
orthovanadate, 1 mM β-glycerophosphate, and protease inhibi-
tor cocktail; Roche). An equal amount of each protein lysate was
incubated with anti-FLAG M2 Affinity Gel (Sigma-Aldrich) for
1 h at 4°C. The immune complexes and protein lysates were
analyzed by Western blot with anti-LKB1 and anti-MO25 anti-
body. The immune complexes were in parallel subjected to liq-
uid chromatography/tandem mass spectrometry (LC–MS/MS)
analysis.
SDS-PAGE
For LC–MS/MS analysis, protein samples were boiled for 5 min
and resolved in 12.5% acrylamide gels, using a Mini-Protean II
electrophoresis cell (Bio-Rad). A constant voltage of 150 V was
applied for 45 min. Gels were fixed in a solution containing 10%
acetic acid and 40% ethanol for 30 min and stained overnight in
Sypro Ruby (Bio-Rad). Gels were then washed in a solution
containing 10% ethanol and 7% acetic acid for 30 min, and the
image was acquired using a Typhoon Trio scanner (GE Health-
care). Each lane was cut in slices and subjected to tryptic di-
gestion, followed by LC–MS/MS analysis.
Tryptic digestion
Gel bands were sliced into three small pieces, which were
washed in milli-Q water. Reduction and alkylation were per-
formed using 10 mM dithiothreitol in 50 mM ammonium bi-
carbonate at 56°C for 20 min, followed by iodoacetamide
(50 mM iodoacetamide in 50 mM ammonium bicarbonate) for
another 20 min in the dark. Gel pieces were dried and incubated
with trypsin (12.5 µg/ml in 50 mM ammonium bicarbonate) for
20 min on ice. After rehydration, the trypsin supernatant was
discarded. Gel pieces were hydrated with 50 mM ammonium
bicarbonate and incubated overnight at 37°C. After digestion,
acidic peptides were cleaned with trifluoroacetic acid 0.1% and
dried in an RVC2 25 speedvac concentrator (Martin Christ).
Peptides were resuspended in 10 µl of 0.1% fluoroacetic acid and
sonicated for 5 min before analysis.
LC-MS analysis
LC was performed using an NanoAcquity nano-HPLC (Waters),
equipped with a Waters BEH C18 nano-column (200 mm ×
75 µm; internal diameter, 1.8 µm), A chromatographic ramp of
30 min (5–60% ACN) was used with a flow rate of 300 nl/min.
Mobile phase A was water containing 0.1% vol/vol formic acid,
and mobile phase B was ACN containing 0.1% vol/vol formic
acid. A lock mass compound [Glu1]-fibrinopeptide B (100 fmol/
µl) was delivered by an auxiliary pump of the LC system at 500
nl/min to the reference sprayer of the NanoLockSpray (Waters)
source of the mass spectrometer.
LC was connected online to a Synapt G2Si electrospray ioni-
zation Q-Mobility-TOF mass spectrometer (Waters) equipped
with an ion mobility chamber (T-Wave-IMS) for high-definition
data acquisition analyses. All analyses were performed in positive-
mode electrospray ionization. Data were postacquisition lockmass
corrected using the double-charged monoisotopic ion of [Glu1]-
fibrinopeptide B. Accurate mass LC-MS data were collected in
hexadehydro-Diels–Aldermode, which enhances signal intensities
using the ion mobility separation step.
Database searching was performed using Mascot 2.2.07
(Matrixscience) against a Uniprot-Swissprot database filled only
with entries corresponding to Homo sapiens (without isoforms).
For protein identification, the following parameters were adopted:
carbamidomethylation of cysteines (C) as fixed modification, ox-
idation of methionines (M) as variable modification, 15 ppm of
peptide mass tolerance, 0.2 D fragment mass tolerance, ≤3 missed
cleavage points, and peptide charges of +2 and +3.
Progenesis LC-MS software analysis
Progenesis LC-MS (v2.0.5556.29015, Nonlinear Dynamics) was
used for the label-free differential protein expression analysis.
One of the runswas used as the reference towhich the precursor
masses in all other samples were aligned. Only features com-
prising charges of 2+ and 3+ were selected. The raw abundances
of each feature were automatically normalized and logarith-
mized against the reference run. Samples were grouped in ac-
cordance to the comparison being performed, and ANOVA was
performed. A peak list containing the information of all the
features was generated and exported to the Mascot search en-
gine (Matrix Science). This file was searched against a Uniprot/
Swissprot database under the conditions stated in the previous
section, and the list of identified peptides was imported back to
Progenesis LC-MS. Protein quantitationwas performed based on
the three most intense nonconflicting peptides (peptides oc-
curring in only one protein), except for proteins with only two
nonconflicting peptides. The significance of expression changes
was tested at the protein level, and proteins identified with at
least two peptides, an ANOVA P value ≤0.05, and a ratio >1.5 in
either direction were selected for further analyses.
Gene expression microarrays
Gene expression analysis of tumors from differentmousemodels
(the original Ptenpc−/−mousemodel [Chen et al., 2005] versus the
Ptenpc+/− Lkb1pc−/− generated in this study) was performed using
GeneChip Mouse Transcriptome Array 1.0 (Affymetrix). Differ-
ential expression was obtained using Transcriptome Analysis
Console v4.0. Expression data were normalized and background-
and batch-corrected using the Signal Space Transformation-
Robust Multi-Chip Analysis implemented in that software.
Data are deposited in GEO (GSE133837).
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Total RNA was extracted from formalin-fixed and paraffin-
embedded (FFPE) tissue using RNAstorm FFPE RNA extrac-
tion kit (Cell Data Sciences) according to the manufacturer’s
instructions. cDNAs from a total of 12 ng RNA were generated,
fragmented, biotinylated, and hybridized to the GeneChip
Mouse Transcriptome Array 1.0. The arrays were washed and
stained on a GeneChip Fluidics Station 450 (Affymetrix);
scanning was performed with the GeneChip Scanner 3000 7G
and image analysis with the Affymetrix GeneChip Command
Console Scan Control. Gene set enrichment analysis was
performed using the MSigDB database (Subramanian et al.,
2005).
Next-generation sequencing and copy number variation (CNV)
calling
DNA was extracted from FFPE tumor blocks positive for tumor
content using the FFPE Tissue DNA kit (Qiagen). DNA was
quantified with the Quant-iT high-sensitivity PicoGreen double-
stranded DNA Assay Kit (Invitrogen), and quality control was
performed with the Illumina FFPE quality control kit (WG-321-
1001). Libraries for next-generation targeted sequencing were
constructed from 40 ng of DNA using a customized panel
(Generead DNaseqMix-n-Match Panel v2; Qiagen) as previously
described (Mateo et al., 2015). CNVs were assessed from the
aligned sequence files (.bam) using CNVkit v0.7.3 (Seed et al.,
2017; Talevich et al., 2016; Turajlic et al., 2018).
Statistics and reproducibility
No statistical method was used to predetermine sample size.
The experiments were not randomized. The investigators were
not blinded to allocation during experiments and outcome assess-
ment. n values represent the number of independent experiments
performed, the number of individual mice, or the number of patient
specimens. Unless otherwise stated, data analyzed byparametric tests
are represented by the mean ± SEM of pooled experiments and the
median ± interquartile range for experiments analyzed by nonpara-
metric tests. For each independent in vitro experiment, at least three
technical replicates were used, and a minimum number of three
experiments was performed to ensure adequate statistical power.
In the in vitro experiments, normal distribution was assumed, and
one-sample t tests were applied for one-component comparisons
with control and Student’s t test for two-component comparisons.
For in vivo experiments, D’Agostino–Pearson, Shapiro–Wilk, and
Kolmogorov–Smirnov normality tests were applied. Student’s
t test was used to compare data with normal distribution, and
nonparametric Mann–Whitney U exact test was used to analyze
samples not following a normal distribution. The confidence
level used for all the statistical analyses was 95% (α = 0.05).
Two-tailed statistical analysis was applied for experimental
design without predicted result, and one-tailed for validation or
hypothesis-driven experiments. GraphPad Prism 8.0.2 soft-
ware was used for statistical calculations.
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Figure S1. Consequences of aberrations in Lkb1 or its targets in murine and human prostate tissue. (A) Analysis of Lkb1 gene expression by qRT-PCR in
Lkb1pc+/+ (n = 5) and Lkb1pc−/− (n = 5) mice. Data were normalized to Gapdh expression. (B)Western blot analysis for Lkb1 protein expression in Lkb1pc+/+ (n = 5)
and Lkb1pc−/− (n = 5) mice. (C) Analysis of Lkb1 gene expression by qRT-PCR in Ptenpc+/− Lkb1pc+/+ (n = 3), Ptenpc+/− Lkb1pc+/− (n = 3), and Ptenpc+/− Lkb1pc−/− (n = 3)
mice. Data are normalized to Gapdh expression. (D)Western blot analysis of Lkb1 and Pten protein expression in Ptenpc+/− Lkb1pc+/+ (n = 3), Ptenpc+/− Lkb1pc+/−
(n = 3), and Ptenpc+/− Lkb1pc−/− (n = 3) mice. (E)Quantification of ventral (VP), dorsolateral (DLP) and anterior (AP) prostate weight in Lkb1pc+/+ and Lkb1pc−/−mice
(n = 27; two lobes per mouse). (F) Immunohistochemical images of AR staining in prostate tissue in Ptenpc+/− Lkb1pc+/+ mice (upper panels) and prostate tumors
and lung metastatic lesions in Ptenpc+/− Lkb1pc−/−mice (lower panels). (G) Lollipop representation of LKB1 point mutations in PCa (Abida et al., 2017; Abida et al.,
2019; Armenia et al., 2018; Cancer Genome Atlas Research Network, 2015; Fraser et al., 2017; Gerhauser et al., 2018; Kumar et al., 2016; Taylor et al., 2010) and
lung adenocarcinoma (Imielinski et al., 2012; Weinstein et al., 2013; Jordan et al., 2017) datasets. (H) Incidence of LKB1 genomic alterations in metastatic
specimens of patients with metastatic PCa (Armenia et al., 2018). Cases without LKB1 homozygous deletion (LKB1 not homdel); cases with LKB1 homozygous
deletion (homdel). Not LN, metastasis identified in all analyzed tissues except for lymph node. Numbers below the graph indicate total number of analyzed
metastatic samples. (I) Incidence of genomic aberrations in metastatic lesions in lung, lymph nodes, bone, liver, and other tissues in patients with metastatic
PCa for the indicated genes (LKB1 targets; Armenia et al., 2018). (J) Incidence of LKB1 genomic alterations in metastatic specimens of patients with metastatic
PCa (Armenia et al., 2018). Cases without SIK3 homozygous deletion (SIK3 not homdel); cases with SIK3 homozygous deletion (homdel). Not bone, metastasis
identified in all analyzed tissues except for bone; not lung, metastasis identified in all analyzed tissues except for lung. Numbers below the graph indicate total
number of analyzed metastatic samples. (K) Incidence of LKB1 and/or SIK3 genomic alterations in metastatic specimens of patients with metastatic PCa
(Armenia et al., 2018). Cases without LKB1 and/or SIK3 homozygous deletion (Rest); cases with LKB1 and/or SIK3 homozygous deletion (homdel). Not bone,
metastasis identified in all analyzed tissues except for bone; not lung, metastasis identified in all analyzed tissues except for lung. Numbers below the graph
indicate total number of analyzed metastatic samples. Statistic tests: one-tailed Mann–Whitney test (A, C, and E); Fisher exact test (J and K). n.s., not sig-
nificant; *, P < 0.05; **, P < 0.01. Error bars represent SEM.
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Figure S2. Pathological and molecular characterization of Lkb1 perturbations in murine and human prostate cells. (A) Immunohistochemical images of
prostate tissue in Ptenpc+/− Lkb1pc+/+ and Ptenpc+/− Lkb1pc−/− mice. Staining as indicated: p-AMPK (Thr172). (B) Representative immunohistochemical images of
prostate tissue in Ptenpc+/− Lkb1pc+/+ and Ptenpc+/− Lkb1pc−/−mice. Staining as indicated: H&E, pS6 (Ser235/236), and p63. (C) Analysis of Krt5 gene expression by
qRT-PCR in Ptenpc+/− Lkb1pc+/+ (n = 3), Ptenpc+/− Lkb1pc+/− (n = 3), and Ptenpc+/− Lkb1pc−/− (n = 3) mice. Data are normalized to Gapdh expression. (D) Gene set
enrichment analysis of the squamous cell carcinoma signature in Ptenpc+/− Lkb1pc−/− (SCC-squamous cell carcinoma) and Ptenpc−/− Lkb1pc+/+ (PADC-prostate
adenocarcinoma) mice. (E) Representative immunofluorescence images (left) of Ki67 (green) and CK5 (red), with quantification of double positive cells (right) in
prostate tissue of Ptenpc−/− Lkb1pc+/+ and Ptenpc+/− Lkb1pc−/− mice. (F) Analysis of LKB1 gene expression by qRT-PCR in DU145 cells with ectopic expression of
WT LKB1 (LKB1WT), the kinase-defective LKB1-K78I mutant (LKB1K78I), or transduced with mock vector (pBABE; n = 6; independent experiments). Data are
normalized to control (pBABE; dashed line). (G) Effect of LKB1WTand LKB1K78I expression on cellular growth (n = 3; independent experiments). (H) Quanti-
fication of invasion (C; n = 4, independent experiments) in LKB1WT, the LKB1K78I, or pBABE-transduced DU145 cells. Data are normalized to control (pBABE;
dashed line). (I) Western blot analysis for LKB1 protein expression in harvested xenograft tumors (n = 3 samples per condition). (J) Metastatic capacity of
control (pBABE) and LKB1WT- and LKB1K78I-expressing DU145 cells using intracardiac xenotransplant assays. Quantification (left) and representative ventral
view (right) of luciferase-dependent signal intensity of DU145 cells captured on day 23. Statistic tests: one-tailed Mann–Whitney test (C, E, and J); one-sample
t test (F and H); *, P < 0.05; **, P < 0.01; ****, P < 0.0001. Error bars represent SEM.
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Figure S3. Molecular analysis of LKB1 reexpression in human PCa cells. (A)Western blot analysis for LKB1 and MO25 protein expression of input and flag
immunoprecipitates in DU145 cell line with ectopic expression of Flag-tagged LKB1WT and LKB1K78I. (B) Picture of SDS-PAGE gel with separation of im-
munoprecipitated proteins. Blue squares indicate areas selected for subsequent LC-MS–based identification and quantitation. (C) Representative analysis of
relative MO25α and MO25β mRNA abundance by qRT-PCR in DU145 cells (n = 3). (D) Representative analysis of MO25α gene expression by qRT-PCR in DU145
cells transduced with scramble shRNA (shCtrl) or two independent shRNA (shMO25α 02; shMO25α 04; n = 3). (E and F) Effect of MO25α gene silencing on
cellular growth (E; n = 3; independent experiments) and anchorage independent growth (F; n = 5; independent experiments; data are normalized to control;
shCtrl, dashed line). (G) Representative Western blot analysis using AMPK motif antibody in control and LKB1WT- and LKB1K78I-expressing cells (n = 3).
(H) Representative Western blot analysis of LKB1, p-AMPK, p-ACC, p-Raptor, Raptor, and β-actin protein expression in control and LKB1WT- and LKB1K78I-
expressing cells (n = 5). (I) Analysis of LKB1 gene expression by qRT-PCR in DU145 cells with ectopic expression of LKB1WT, LKB1K78I, and LKB1D194A or
transduced with mock vector (pBABE; n = 3; independent experiments). Data are normalized to control (pBABE; dashed line). (J) Effect of LKB1WT, LKB1K78I, and
LKB1D194A expression on cell growth (n = 3; independent experiments). (K)Western blot analysis using AMPKmotif antibody in control and LKB1WT-, LKB1K78I-,
and LKB1D194A-expressing DU145 cells. (L) Representative Western blot analysis for LKB1, p-AMPK, p-ACC, p-Raptor, Raptor, and HSP90 protein expression in
control and LKB1WT-, LKB1K78I-, and LKB1D194A-expressing DU145 cells (n = 5). (M) Western blot analysis of LKB1 protein expression in harvested xenograft
tumors (n = 5 samples per condition). (N) Effect of LKB1 reconstitution in DU145 cells with ectopic expression LKB1WT, the kinase-defective mutants (LKB1K78I,
LKB1D194A) or infected withmock vector (pBABE) on tumor weight (left). Representative picture of harvested tumors (right) in xenotransplantation experiments
(n = 20 injections per condition). (O)Quantification (left) and representative image (right) of Ki67 staining in harvested xenograft tumors in control and LKB1WT-,
LKB1K78I-, and LKB1D194A-expressing DU145 cells. Statistic test: one-sample t test (I); one-tailed Mann–Whitney test (N and O). *, P < 0.05; ****, P < 0.0001.
Error bars represent SD (C, E, and F) and SEM (I, J, N, and O).
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Tables S1–S10 are provided online as separate Excel files. Table S1 shows the incidence of metastasis in indicated tissues in
Ptenpc+/− Lkb1pc−/− mice. Table S2 shows STK11 in primary tumors and metastasis (Armenia et al., 2018). Table S3 shows the
incidence of primary prostate tumors andmetastasis in patients with indicated LKB1 genomic status (Armenia et al., 2018). Table S4
shows the frequency of copy number alterations (Armenia et al., 2018). Table S5 shows the frequency of coexisting mutations with
LKB1 deletion among the top genes with copy number aberrations in the metastatic specimens (Armenia et al., 2018). Table S6
shows the incidence of primary prostate tumors and metastasis in patients with indicated SIK3 genomic status (Armenia et al.,
2018). Table S7 shows the incidence of primary prostate tumors and metastasis in patients with indicated LKB1 and SIK3 genomic
status (Armenia et al., 2018). Table S8 lists differentially expressed genes inmicrodissected specimens from Ptenpc+/− Lkb1pc−/− (G2)
versus Ptenpc−/− Lkb1pc+/+ mice (G5). Table S9 shows interactome analysis of LKB1 using Flag immunoprecipitation. Table S10 shows
the Universal Probe Library (Roche) primers and probes used in this study.
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